Evox Therapeutics Analysis
What is Evox Therapeutics?
Proprietary ExoEdit™ gene editing in exosomes for rare neurodegenerative diseases
Location
Oxford, United Kingdom
Employees
11-50
Founded
2016
Product Features & Capabilities
- ExoEdit™ gene editing platform
- Exosome-based CRISPR/Cas delivery
- Targeted delivery to central nervous system
- Therapeutic pipeline for rare neurodegenerative diseases
Other Considerations
Named in Nature Biomedical Engineering publication; Co-founded by Professor Matthew Wood and Dr. Per Lundin; Backed by Oxford Sciences Innovation; Developed ExoEdit™ technology from Oxford and Karolinska Institutet research; Pipeline includes therapies for ALS and Parkinson's disease
